Oral human papillomavirus in healthy individuals: a systematic review of the literature
AR Kreimer, RK Bhatia, AL Messeguer… - Sexually transmitted …, 2010 - journals.lww.com
Background: Human papillomavirus type 16 (HPV16) is a common infection in the
anogenital tract. HPV16 DNA detected in oral specimens has recently been identified as a …
anogenital tract. HPV16 DNA detected in oral specimens has recently been identified as a …
E UROGIN 2014 roadmap: Differences in human papillomavirus infection natural history, transmission and human papillomavirus‐related cancer incidence by gender …
AR Giuliano, AG Nyitray, AR Kreimer… - … journal of cancer, 2015 - Wiley Online Library
Human papillomaviruses (HPVs) cause cancer at multiple anatomic sites in men and
women, including cervical, oropharyngeal, anal, vulvar and vaginal cancers in women and …
women, including cervical, oropharyngeal, anal, vulvar and vaginal cancers in women and …
[HTML][HTML] Evidence for single-dose protection by the bivalent HPV vaccine—review of the Costa Rica HPV vaccine trial and future research studies
AR Kreimer, R Herrero, JN Sampson, C Porras… - Vaccine, 2018 - Elsevier
Abstract The Costa Rica Vaccine Trial (CVT), a phase III randomized clinical trial, provided
the initial data that one dose of the HPV vaccine could provide durable protection against …
the initial data that one dose of the HPV vaccine could provide durable protection against …
[HTML][HTML] Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica
R Herrero, W Quint, A Hildesheim, P Gonzalez… - PloS one, 2013 - journals.plos.org
Background Human papillomavirus (HPV) infection, particularly with type 16, causes a
growing fraction of oropharyngeal cancers, whose incidence is increasing, mainly in …
growing fraction of oropharyngeal cancers, whose incidence is increasing, mainly in …
Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine
AR Kreimer, AC Rodriguez… - Journal of the …, 2011 - academic.oup.com
Background Three-dose regimens for human papillomavirus (HPV) vaccines are expensive
and difficult to complete, especially in settings where the need for cervical cancer prevention …
and difficult to complete, especially in settings where the need for cervical cancer prevention …
[HTML][HTML] Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer
AR Kreimer, M Johansson, T Waterboer… - Journal of clinical …, 2013 - ncbi.nlm.nih.gov
Purpose Human papillomavirus type 16 (HPV16) infection is causing an increasing number
of oropharyngeal cancers in the United States and Europe. The aim of our study was to …
of oropharyngeal cancers in the United States and Europe. The aim of our study was to …
[HTML][HTML] Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials
AR Kreimer, F Struyf… - The lancet …, 2015 - thelancet.com
Background There is some evidence to suggest that one or two doses of the HPV vaccine
provides similar protection to the three-dose regimen. The main aim of the study was to …
provides similar protection to the three-dose regimen. The main aim of the study was to …
Incidence and clearance of oral human papillomavirus infection in men: the HIM cohort study
AR Kreimer, CMP Campbell, HY Lin, W Fulp… - The Lancet, 2013 - thelancet.com
Background Oral human papillomavirus (HPV) infection causes a subset of oropharyngeal
cancers. These cancers disproportionately affect men, are increasing in incidence, and have …
cancers. These cancers disproportionately affect men, are increasing in incidence, and have …
[PDF][PDF] HPV16 E7 genetic conservation is critical to carcinogenesis
Although most cervical human papillomavirus type 16 (HPV16) infections become
undetectable within 1–2 years, persistent HPV16 causes half of all cervical cancers. We …
undetectable within 1–2 years, persistent HPV16 causes half of all cervical cancers. We …
Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial
AR Kreimer, P González, HA Katki, C Porras… - The lancet …, 2011 - thelancet.com
Background Anal cancer remains rare (incidence of about 1· 5 per 100 000 women yearly),
but rates are increasing in many countries. Human papillomavirus (HPV) 16 and 18 …
but rates are increasing in many countries. Human papillomavirus (HPV) 16 and 18 …